Schistosome voltage-gated calcium channel beta subunit variant (SmCavβ)

The Schistosome voltage-gated calcium channel beta subunit variant (SmCavβ) is a regulatory protein essential for the function of high-voltage-activated calcium channels in Schistosoma parasites (Kohn et al., 2001, Journal of Biological Chemistry). It is a critical component of the parasite's neuromuscular system and is essential for maintaining tegumental integrity (Greenberg, 2014, International Journal for Parasitology: Drugs and Drug Resistance). This specific variant is widely recognized as a primary molecular target of Praziquantel, the gold-standard treatment for schistosomiasis (McCusker et al., 2019, PLOS Pathogens). Unlike mammalian calcium channel subunits, SmCavβ possesses a unique structure that allows Praziquantel to act as an allosteric modulator, triggering a rapid and sustained influx of calcium ions into the parasite (Park & Marchant, 2020, Trends in Parasitology). This calcium overload results in immediate spastic paralysis and severe damage to the worm's outer protective layer, known as the tegument (Doenhoff et al., 2008, Clinical Microbiology Reviews). The resulting damage exposes parasite antigens to the host's immune system, facilitating the clearance of the infection (Wang et al., 2013, PLOS Neglected Tropical Diseases). Understanding this target is vital for addressing the potential emergence of drug resistance in endemic regions (Cioli et al., 2014, Parasitology Research).

Other names

SmβvSmCavβ1Voltage-dependent calcium channel beta subunit variantPraziquantel targetSchistosoma mansoni Cavβ

Allosteric modulation of the voltage-gated calcium channel complex, leading to increased calcium influx, muscle paralysis, and tegumental disruption.